ArticleAnalytical and bioanalytical chemistry2026
Orthogonality-driven offline two-dimensional liquid chromatography coupled with high-resolution mass spectrometry for comprehensive chemical profiling and quality marker screening of Renshen Guben oral liquid.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Traditional Chinese patent medicines present formidable analytical challenges due to their multi-herb composition, extreme polarity diversity, and vast concentration disparities among constituents, rendering conventional one-dimensional liquid chromatography-mass spectrometry (1D LC-MS) insufficient for comprehensive quality assessment. This study establishes an orthogonality-driven offline two-dimensional liquid chromatography system (HILIC × RPLC) coupled with Q-Orbitrap mass spectrometry for in-depth chemical profiling and rational quality marker (Q-marker) screening of Renshen Guben oral liquid (RSGB), a clinically used immunomodulatory formulation comprising ten herbal ingredients. The 2D-LC platform was systematically optimized and validated, achieving a ~50-fold improvement over 1D LC-MS in component coverage. Global natural products social molecular networking (GNPS) was employed to visualize MS/MS spectral similarity relationships, facilitating confident annotation of structurally related analogues across 13 chemical classes. A total of 260 compounds were identified, among which 48 were verified against reference standards. Building upon this comprehensive chemical foundation, a multidimensional Q-marker screening strategy was devised by integrating network pharmacology prediction, molecular docking evaluation against the core immune-related target HSP90AA1, and chromatographic fingerprint correlation of ten constituent herbs, ultimately designating 12 compounds from eight distinct herbs as Q-markers. To address the wide dynamic range in component abundance, an adjusted multiple reaction monitoring (MRM) method utilizing triple quadrupole mass spectrometry was developed, enabling simultaneous quantification spanning three orders of magnitude. Method validation demonstrated excellent linearity (R
Indexed as
Identifiers
42848077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.